Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct)

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Mutch, D; Orlando, M; Teneriello, T; Gordon, A; McMeekin, S; Goss, T; Scribner, D; Naumann, R; Secord, AA; Wang, Y

Published Date

  • October 1, 2005

Published In

Volume / Issue

  • 3 / 2

Start / End Page

  • 262 - 262

Published By

Pages

  • 1

International Standard Serial Number (ISSN)

  • 1359-6349